Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Myasthenia Gravis 4

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × zilucoplan × Clear all
NCT06471361 2026-03-27

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 3 Completed
31 enrolled 11 charts

Myasthenia Gravis

NCT05514873 2025-09-03

An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

UCB Pharma

Phase 3 Completed
26 enrolled 14 charts

Myasthenia Gravis

NCT04115293 2025-07-16

RAISE

UCB Pharma

Phase 3 Completed
174 enrolled 19 charts

Myasthenia Gravis

NCT03315130 2022-07-27

Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

UCB Pharma

Phase 2 Completed
45 enrolled 21 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡